



3-305 Industrial Parkway South  
Aurora, Ontario, Canada, L4G 6X7  
Phone: (905) 841-2300  
Fax: (905) 841-2244  
Web: [www.helixbiopharma.com](http://www.helixbiopharma.com)

**December 18, 2014**  
**NEWS RELEASE**

## **HELIX ANNOUNCES THE RESULTS OF ITS ANNUAL GENERAL MEETING**

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“**Helix**”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that its Annual General Meeting (the “**Meeting**”) was held today as scheduled.

Shareholders represented in person or by proxy at the Meeting elected Messrs. Yvon Bastien, Sylwester Cacek, Slawomir Majewski, Marek Orłowski, Sven Rohmann, Robert A. Verhagen and Stacy L. Wills as directors of the Company for the ensuing year or until such time that their respective successors are elected or appointed or they otherwise cease to hold office. In excess of 99.9% of votes cast at the Meeting, in person or by proxy, voted “for” the election of each of these directors.

In addition, BDO Canada LLP, Chartered Accountants, were appointed as auditors.

At a board meeting held after the Meeting, Mr. Yvon Bastien was appointed Chairman of the Board, Mr. Verhagen was appointed as President and Chief Executive Officer and Mr. Frank Michalargias was appointed as Chief Financial Officer. Following the Meeting Mr. Verhagen said, “We would like to thank Helix’s shareholders for their participation in this process, and the support that they have shown the Company, its board, and its management. We look forward to a successful and exciting year as we continue to move the Company forward.”

### **About Helix BioPharma Corp.**

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b drug candidate. Helix is currently listed on the TSX and FSE under the symbol “HBP”.

#### **Investor Relations:**

Helix BioPharma Corp.

Tel: (905) 841-2300

Email: [ir@helixbiopharma.com](mailto:ir@helixbiopharma.com)

### **Forward-Looking Statements and Risks and Uncertainties**

*This news release contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements, which may be identified by words including, without limitation, “moving forward” and other similar expressions, are intended to provide information about management’s current plans and expectations regarding future operations.*

*Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, those described in Helix's Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at [www.sedar.com](http://www.sedar.com) (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.*

*Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.*

---